RESPIRATORY SYNCYTIAL VIRUS VACCINES clinical trials

Immunogenicity after a prime dose and revaccination with adjuvanted RSVPreF3 vaccine in the most elderly and frail population – an open-labeled phase IIIb-trial RSV Immunogenicity Study in the Elderly (RISE)

This study, called RISE, looks at how well the Arexvy vaccine works in older adults to protect against RSV, a common chest infection. We're checking how the body's defence system responds to the vaccine in people aged 60-65 and those aged 80 and over.